Advertisement

Topics

US FDA approve Seattle Genetics' Adcetris for pcALCL and CD30─expressing mycosis fungoides

07:33 EST 11 Nov 2017 | PharmaBiz

Seattle Genetics has announced that the US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell

Original Article: US FDA approve Seattle Genetics' Adcetris for pcALCL and CD30─expressing mycosis fungoides

NEXT ARTICLE

More From BioPortfolio on "US FDA approve Seattle Genetics' Adcetris for pcALCL and CD30─expressing mycosis fungoides"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...